Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency
Concomitant use of clopidogrel and strong CYP2C19-inhibiting PPIs was not associated with a higher cardiovascular risk compared with concomitant use of clopidogrel and weak or non-CYP2C19-inhibiting PPIs. This large-scale study does not support the clinical significance of potential interactions between PPIs and clopidogrel.
Authors
- Paul Nagy (ORCID: https://orcid.org/0000-0001-5108-7749)
- Phung‐Anh Nguyen (ORCID: https://orcid.org/0000-0002-7436-9041)
- S M Kim
- Christianus Heru Setiawan (ORCID: https://orcid.org/0000-0003-4860-1115)
- George Hripcsak (ORCID: https://orcid.org/0000-0003-2664-7614)
- Martin Bk
- Seng Chan You (ORCID: https://orcid.org/0000-0002-5052-6399)
- Subin Kim (ORCID: https://orcid.org/0000-0001-7155-2273)
- Jimyung Park (ORCID: https://orcid.org/0000-0002-6998-2546)
- Kyung Joo Lee
- Haeun Lee
- Hsin Yi Chen
- Jason C. Hsu
- Phan Thanh-Phuc
- Min-Huei Hsu
- Seung In Seo
- Woon Geon Shin
Institutions
- Johns Hopkins University (US)
- Hallym University (KR)
- Sanata Dharma University (ID)
- Yonsei University (KR)
- Columbia University Irving Medical Center (US)
- Johns Hopkins Medicine (US)
- Sacred Heart Hospital (IE)
- Taipei Medical University Hospital (TW)
- Hallym University Kangnam Sacred Heart Hospital (KR)
- Sacred Heart Hospital (US)
- Kangdong Sacred Heart Hospital (KR)
- Yonsei University Health System (KR)
- Taipei Medical University (TW)
- Cardinal Tien College of Healthcare and Management (TW)
Publication Details
- Journal
- Arteriosclerosis Thrombosis and Vascular Biology
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1161/atvbaha.125.323399
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 30.07